These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15300182)

  • 1. Modulation of resistance to regional chemotherapy in the extremity melanoma model.
    Grubbs EG; Ueno T; Abdel-Wahab O; Cheng TY; Pruitt SK; Michael Colvin O; Friedman HS; Tyler DS
    Surgery; 2004 Aug; 136(2):210-8. PubMed ID: 15300182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-transit melanoma: the role of alkylating-agent resistance in regional therapy.
    Grubbs EG; Abdel-Wahab O; Cheng TY; Abdel-Wahab Z; Peterson B; Pruitt SK; Colvin OM; Friedman HS; Tyler DS
    J Am Coll Surg; 2004 Sep; 199(3):419-27. PubMed ID: 15325612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI.
    Padussis JC; Steerman SN; Tyler DS; Mosca PJ
    Int J Hyperthermia; 2008 May; 24(3):239-49. PubMed ID: 18393002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
    Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
    Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
    Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
    Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
    Ongaro A; Pellati A; De Mattei M; De Terlizzi F; Rossi CR; Campana LG
    Anticancer Drugs; 2015 Mar; 26(3):284-92. PubMed ID: 25514113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
    Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
    Neuwelt EA; Pagel MA; Hasler BP; Deloughery TG; Muldoon LL
    Cancer Res; 2001 Nov; 61(21):7868-74. PubMed ID: 11691805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
    Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
    Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
    Gallo JM; Brennan J; Hamilton TC; Halbherr T; Laub PB; Ozols RF; O'Dwyer PJ
    Cancer Res; 1995 Oct; 55(20):4507-11. PubMed ID: 7553617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells.
    Schnelldorfer T; Gansauge S; Gansauge F; Schlosser S; Beger HG; Nussler AK
    Cancer; 2000 Oct; 89(7):1440-7. PubMed ID: 11013356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
    Kroon HM; Lin DY; Kam PC; Thompson JF
    Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models.
    Beasley GM; Kahn L; Tyler DS
    Surg Oncol Clin N Am; 2008 Oct; 17(4):731-58, vii-viii. PubMed ID: 18722915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.
    Hoving S; Brunstein F; aan de Wiel-Ambagtsheer G; van Tiel ST; de Boeck G; de Bruijn EA; Eggermont AM; ten Hagen TL
    Cancer Res; 2005 May; 65(10):4300-8. PubMed ID: 15899822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.